Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.79 |
| ▸ | HTR2C | P28335 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30704389 | 1.00 | HTR2A (0.79) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL31078590 | 0.98 | KDM4E (0.79) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL10154860 | 0.90 | HTR2A (0.65) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Pnu-22394 SCHEMBL29388570 | 0.88 | HTR2C (1.00) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Pnu-22394 SCHEMBL5364550 | 0.88 | HTR2C (1.00) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL967629 | 0.87 | HTR2C (0.79) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Pnu-22394 SCHEMBL29779480 | 0.87 | KDM4E (1.00) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL30396890 | 0.85 | KDM4E (0.79) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL9057430 | 0.85 | KDM4E (0.79) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL30569677 | 0.80 | HTR2A (0.51) | HTR2AHTR2CKDM4EALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | disclosed |
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | disclosed |
| US-11274098-B2 | Tricyclic compounds for use in treatment of proliferative disorders | Argonaut Therapeutics Limited (GB) | 2022-03-15 | — | — | US | disclosed |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| US-20090023756-A1 | SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS | PFIZER INC | 2009-01-22 | — | — | US | disclosed |
| EP-1996587-A1 | SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007096743-A1 | SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1015451-B1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA NV (BE) | 2003-06-18 | — | — | EP | disclosed |
| US-6506768-B2 | Serotonergic modulators; for treatment of disorders of the central nervous system including psychotic disorders, hypertension and vascular disorders, migraine | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-14 | — | — | US | disclosed |
| US-20020103209-A1 | Tetrahydro gamma-carbolines | KENNIS LUDO EDMOND JOSEPHINE (BE) | 2002-08-01 | — | — | US | disclosed |
| US-6303614-B1 | FOR THERAPY PSYCHOTIC DISORDER SELECTED FROM DEPRESSION, ANXIETY OR PSYCHOSIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-16 | — | — | US | disclosed |
| EP-1015451-A1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-05 | — | — | EP | disclosed |
| EP-0905136-A1 | Tetrahydro gamma-carbolines | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-03-31 | — | — | EP | disclosed |
| WO-1999012926-A1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023756-A1 | SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS | PDE12, PDE5A, PDE10A | HTR2A 481/4885HTR2C 487/4885KDM4E 1138/4885 |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | HTR2A 2940/4885HTR2C 3749/4885KDM4E 4065/4885 |
| US-11274098-B2 | Tricyclic compounds for use in treatment of proliferative disorders | PRMT5, HDAC5, CDK15 | HTR2A 3699/4885HTR2C 3015/4885KDM4E 243/4885 |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | HTR2A 2941/4885HTR2C 3649/4885KDM4E 4066/4885 |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | PRMT5, HDAC5, CDK15 | HTR2A 3699/4885HTR2C 3015/4885KDM4E 243/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | HTR2A 2940/4885HTR2C 3749/4885KDM4E 4065/4885 |
| US-20020103209-A1 | Tetrahydro gamma-carbolines | OPRD1, CYP1B1, CBR1 | HTR2A 444/4885HTR2C 94/4885KDM4E 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.